Previous studies have demonstrated that reactivation of the MAPK/ERK pathway and feedback activation of the PI3K/AKT pathway during the use of vemurafenib can lead to drug resistance in thyroid cancer cells 23. This evidence concerns the gene AKT1 and thyroid gland carcinoma.